| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Financial Officer
2 companies
Teri Loxam is Chief Financial Officer at CMPS, with reported holdings spanning 2 companies. Teri Loxam's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.1M at current prices.
Teri Loxam's largest disclosed position is in CMPS as Chief Financial Officer, worth about $1.3M.
Teri Loxam has 14 Form 4 filings on record from September 2021 to June 2026, across 2 companies: Director at Vaxcyte (PCVX), 2021–2026; Chief Financial Officer at COMPASS Pathways (CMPS), 2024–2026.
The 34 reported transactions were 12 open-market sales, 9 option or other derivative awards, 8 stock awards and 3 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $1.3M.
The largest open-market sale was 6,250 shares of PCVX at an average $116.28 on September 17, 2024, about $727K. Twelve months later PCVX was down 74%.
Both sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.